Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 334   Home Print this page  Email this page Small font size Default font size Increase font size
ORIGINAL ARTICLE
Year : 2020  |  Volume : 12  |  Issue : 1  |  Page : 25-30

Is cystoscopy follow-up protocol safe for low-risk bladder cancer without muscle invasion?


1 Department of Urology, Health Sciences University, Istanbul Training and Research Hospital, Istanbul, Turkey
2 Department of Urology, Health Sciences University, Elazig Training and Research Hospital, Elazig, Turkey
3 Department of Urology, Gebze Fatih State Hospital, Kocaeli, Turkey
4 Department of Pathology, Acibadem Atakent Hospital, Istanbul, Turkey
5 Department of Urology, Florence Nightingale Hospital, Istanbul, Turkey

Correspondence Address:
Dr. Huseyin Aytac Ates
Department of Urology, Gebze Fatih State Hospital, Osman Yilmaz Mah., Gebze 41400, Kocaeli
Turkey
Login to access the Email id


DOI: 10.4103/UA.UA_143_18

PMID: 32015613

Rights and Permissions

Objective: The applicability of cystoscopy follow-up protocol that is indicated for low-risk nonmuscle-invasive bladder cancer (NMIBC) in the guidelines was investigated for our population. Materials and Methods: Patients who underwent transurethral resection with a diagnosis of primary bladder tumor in our clinic within 10 years with low grade of pathology pTa and follow-up periods of at least 5 years were retrospectively reviewed. Fifty-one patients (39 males and 12 females) who were diagnosed with a low-risk NMIBC, had no recurrence at the 3-month control cystoscopy, and followed up for the first 2 years on 3-month basis with cystoscopy were included in the study. Results: The mean age of the patients was 57.37 ± 12.21 years (range: 29–80 years), and the mean duration of recurrence was 25.76 ± 32.45 months. In the cystoscopy follow-ups of 51 patients, up to the 6th month, a total of 12 (24%); up to the 9th month, a total of 21 (41%); up to the 12th month, a total of 30 (59%); up to the 15th month, a total of 36 (71%); up to the 18th month, a total of 36 (71%); up to the 21st month, a total of 39 (77%); and up to the 24th month, a total of 41 (80%) patients were reported to have recurrence. In the case of patients with no recurrence at the 9th month cystoscopy, it was determined that 50% of the patients had recurrence in the first 6 months and 67% in the first 2 years. Conclusion: The majority (80%) of recurrences in low-risk NMIBC occurred in the first 2 years. If the follow-up protocol described in the guidelines had been applied, patients with relapses would have a delay of at least 6 months of diagnosis. Therefore, even if there is no recurrence in the low-risk NMIBC at the 3rd and 9th months, it may be more appropriate to follow the cases in the first 2 years with follow-up cystoscopy every 3 months.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed348    
    Printed10    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal